Revelation Biosciences Stock (NASDAQ:REVB)

Ownership Financials Chart

Previous Close

$1.01

52W Range

$0.88 - $12.88

50D Avg

$1.11

200D Avg

$3.45

Market Cap

$4.06M

Avg Vol (3M)

$70.44K

Beta

-0.08

Div Yield

REVB Company Profile

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Nov 17, 2020

Website

REVB Performance

REVB Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-9.07B	$-7.98M	$-8.66M
Net Income	$-14.87B	$-15.04M	$-120.25K
EBITDA	$-9.07B	$-7.95M	$-8.63M
Basic EPS	$-23.95	$-87.68	$-8.41
Diluted EPS	$-23.95	$-87.68	$-8.41

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
PBM	Psyence Biomedical Ltd.
SPRC	SciSparc Ltd.
GTBP	GT Biopharma, Inc.
ONCO	Onconetix, Inc.
SLXN	Silexion Therapeutics Ltd.
INDP	Indaptus Therapeutics, Inc.